Email Alert | RSS

Journal of Peking University (Health Sciences) ›› 2024, Vol. 56 ›› Issue (2): 284-292. doi: 10.19723/j.issn.1671-167X.2024.02.013

Previous Articles     Next Articles

A unicenter real-world study of the correlation factors for complete clinical response in idiopathic inflammatory myopathies

Zhanhong LAI1,Jiachen LI1,Zelin YUN1,Yonggang ZHANG2,Hao ZHANG3,Xiaoyan XING1,Miao SHAO1,Yuebo JIN1,Naidi WANG1,Yimin LI4,Yuhui LI1,*(),Zhanguo LI1,*()   

  1. 1. Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing 100044, China
    2. Department of Rheumatology and Immunology, Baoding First Hospital, Baoding 071000, Hebei, China
    3. Department of Rheumatology and Immunology, Dalian Municipal Central Hospital, Dalian 116089, Liaoning, China
    4. Department of Rheumatology and Immunology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China
  • Received:2023-09-04 Online:2024-04-18 Published:2024-04-10
  • Contact: Yuhui LI,Zhanguo LI E-mail:liyuhui84@163.com;Li99@bjmu.edu.cn

RICH HTML

   

PDF (PC)

Abstract:

Objective: To investigate the correlation factors of complete clinical response in idiopathic inflammatory myopathies (IIMs) patients receiving conventional treatment. Methods: Patients diagnosed with IIMs hospitalized in Peking University People's Hospital from January 2000 to June 2023 were included. The correlation factors of complete clinical response to conventional treatment were identified by analyzing the clinical characteristics, laboratory features, peripheral blood lymphocytes, immunological indicators, and therapeutic drugs. Results: Among the 635 patients included, 518 patients finished the follow-up, with an average time of 36.8 months. The total complete clinical response rate of IIMs was 50.0% (259/518). The complete clinical response rate of dermatomyositis (DM), anti-synthetase syndrome (ASS) and immune-mediated necrotizing myopathy (IMNM) were 53.5%, 48.9% and 39.0%, respectively. Fever (P=0.002) and rapid progressive interstitial lung disease (RP-ILD) (P=0.014) were observed much more frequently in non-complete clinical response group than in complete clinical response group. The aspartate transaminase (AST), lactate dehydrogenase (LDH), D-dimer, erythrocyte sedimentation rate (ESR), C-reaction protein (CRP) and serum ferritin were significantly higher in non-complete clinical response group as compared with complete clinical response group. As for the treatment, the percentage of glucocorticoid received and intravenous immunoglobin (IVIG) were significantly higher in non-complete clinical response group than in complete clinical response group. Risk factor analysis showed that IMNM subtype (P=0.007), interstitial lung disease (ILD) (P=0.001), eleva-ted AST (P=0.012), elevated serum ferritin (P=0.016) and decreased count of CD4+T cells in peripheral blood (P=0.004) might be the risk factors for IIMs non-complete clinical response. Conclusion: The total complete clinical response rate of IIMs is low, especially for IMNM subtype. More effective intervention should be administered to patients with ILD, elevated AST, elevated serum ferritin or decreased count of CD4+T cells at disease onset.

Key words: Idiopathic inflammatory myopathies, Clinical response, Interstitial lung disease, Risk factors, Autoantibodies

CLC Number: 

  • R593.26

Figure 1

Flow diagram of study design IIMs, idiopathic inflammatory myopathies; EULAR, European League Against Rheumatism; ACR, American College of Rheumatology."

Table 1

Comparison of clinical characteristics between IIMs CCR group and NCCR group"

Variables CCR (n=259) NCCR (n=259) P value
Female 195 (75.3) 190 (73.4) 0.615
Age at onset/years 49.3±15.0 50.2±13.6 0.460
DM 146 (56.4) 127 (49.0) 0.095
ASS 60 (23.2) 63 (24.3) 0.757
IMNM 46 (17.8) 72 (27.8) 0.006
Fever 75 (29.0) 109 (42.1) 0.002
Dyspnea 103 (39.8) 91 (35.1) 0.276
Gottron’s sign/papules 158 (61.0) 166 (64.1) 0.468
Mechanic’s hands 72 (27.8) 82 (31.7) 0.336
Heliotrope rash 99 (38.2) 110 (42.5) 0.325
ILD 159 (61.4) 189 (73.0) 0.005
  RP-ILD 84 (32.4) 111 (42.9) 0.014
  C-ILD 72 (27.8) 67 (25.9) 0.620

Figure 2

Comparison of laboratory features (A) and MSAs/MAAs (B) between IIMs CCR group and NCCR group * P < 0.05, NCCR group compared with CCR group. a, 319 values missing; b, 319 values missing; c, 293 values missing; d, 320 values missing; e, 326 values missing; f, 280 values missing; g, 317 values missing; h, 314 values missing; i, 324 values missing; j, 331 values missing; k, 167 values missing. IIMs, idiopathic inflammatory myopathies; CCR, complete clinical response; NCCR, non-complete clinical response; MSAs, myositis specific antibodies; MAAs, myositis associated antibodies; DM, dermatomyositis; ASS, anti-synthetase syndrome; IMNM, immune-mediated necroti-zing myopathy; ILD, interstitial lung disease; RP-ILD, rapid progressive interstitial lung disease; C-ILD, chronic interstitial lung disease; Anti TIF-1γ, anti-transcriptional intermediary factor 1γ; Anti MDA5, anti-melanoma differentiation-associated protein 5; Anti NXP2, anti-nuclear matrix protein 2; Anti SAE1, anti-small ubiquitin-like modifier activating enzyme 1; Anti Jo-1, anti-histidyl-tRNA synthetase; Anti SRP, anti-signal recognition particle; Anti PL-7, anti-threonyl-tRNA synthetase; Anti PL-12, anti-alanyl-tRNA synthetase; Anti EJ, anti-glycyl-tRNA synthetase; Anti OJ, anti-isoleucyl-tRNA synthetase."

Table 2

Comparison of laboratory features between IIMs CCR group and NCCR group"

Variables CCR (n=259) NCCR (n=259) P value
WBC/(×109/L) 7.53±3.37 7.81±3.66 0.363
Lymphocyte/(×109/L) 1.47±0.84 1.36±0.84 0.146
PLT/(×109/L) 228.0±84.5 223.0±83.1 0.483
ALT/(U/L) 33.0 (20.3, 56.0) 45.5 (20.0, 103.0) 0.509
AST/(U/L) 34.0 (24.2, 69.0) 63.5 (31.0, 132.0) 0.008
LDH/(U/L) 289 (232, 519) 429 (290, 631) 0.001
CK/(U/L) 77.0 (34.5, 251.0) 76.0 (26.8, 775.0) 0.627
D-dimer/(μg/L) 322 (195, 487) 425 (282, 714) 0.002
ESR/(mm/L) 17.5 (8.9, 41.8) 36.5 (12.8, 58.3) 0.003
CRP/(mg/L) 3.43 (0.63, 20.40) 8.03 (2.00, 28.50) 0.002
Ferritin/(μg/L)a 229 (83, 1 116) 566 (272, 1 588) 0.020
IgG/(g/L) 14.50±6.43 13.90±5.37 0.214
C3/(g/L) 1.00±0.27 1.01±0.27 0.760
C4/(g/L) 0.25±0.12 0.24±0.10 0.575

Figure 3

Comparison of peripheral blood lymphocytes between IIMs CCR group and NCCR group IIMs, idiopathic inflammatory myopathies; CCR, complete clinical response; NCCR, non-complete clinical response; T cell, T lymphocyte cell; B cell, B lymphocyte cell; NK cell, natural killer cell; TNF, tumor necrosis factor; IFN, interferon; IL, interleukin."

Table 3

Comparison of initial treatment between IIMs CCR group and NCCR group"

Variables CCR (n=259) NCCR (n=259) P value
Glucocorticoid, n (%) 206 (79.5) 226 (87.3) 0.018
  Prednisone ≤ 15 mg/da 63 (24.4) 49 (19.0) 0.135
  15 mg/d＜prednisone＜30 mg/da 9 (3.5) 9 (3.5) ＞0.999
  Prednisone ≥ 30 mg/da 119 (46.1) 125 (48.4) 0.597
  Pulse IVMP 67 (25.9) 75 (29.0) 0.431
Immunosuppressants, n (%) 166 (64.1) 156 (60.2) 0.365
  CTX 96 (37.1) 94 (36.3) 0.855
  CSA 54 (20.8) 51 (19.7) 0.743
  TAC 10 (3.9) 17 (6.6) 0.166
  MMF 20 (7.7) 11 (4.2) 0.095
JAKi, n (%) 2 (0.8) 8 (3.1) 0.055
IVIG, n (%) 25 (9.7) 42 (16.2) 0.026

Figure 4

Multivariate Logistic regression analysis of factors related to IIMs CCR IIMs, idiopathic inflammatory myopathies; CCR, complete clinical response; IMNM, immune-mediated necrotizing myopathy; ILD, interstitial lung disease; AST, aspartate aminotransferase; T cell, T lymphocyte cell."

1 Tanboon J , Nishino I . Classification of idiopathic inflammatory myopathies: Pathology perspectives[J]. Curr Opin Neurol, 2019, 32 (5): 704- 714.
doi: 10.1097/WCO.0000000000000740
2 DeWane ME , Waldman R , Lu J . Dermatomyositis: Clinical features and pathogenesis[J]. J Am Acad Dermatol, 2020, 82 (2): 267- 281.
doi: 10.1016/j.jaad.2019.06.1309
3 罗澜, 邢晓燕, 肖云抒, 等. 抗合成酶综合征合并心脏受累患者的临床及免疫学特征[J]. 北京大学学报(医学版), 2021, 53 (6): 1078- 1082.
4 Marco JL , Collins BF . Clinical manifestations and treatment of antisynthetase syndrome[J]. Best Pract Res Clin Rheumatol, 2020, 34 (4): 101503.
doi: 10.1016/j.berh.2020.101503
5 Pinal-Fernandez I , Casal-Dominguez M , Mammen AL . Immune-mediated necrotizing myopathy[J]. Curr Rheumatol Rep, 2018, 20 (4): 21.
doi: 10.1007/s11926-018-0732-6
6 Wolstencroft PW , Chung L , Li S , et al. Factors associated with clinical remission of skin disease in dermatomyositis[J]. JAMA Dermatol, 2018, 154 (1): 44- 51.
doi: 10.1001/jamadermatol.2017.3758
7 Lundberg IE , Fujimoto M , Vencovsky J , et al. Idiopathic inflammatory myopathies[J]. Nat Rev Dis Primers, 2021, 7 (1): 86.
doi: 10.1038/s41572-021-00321-x
8 Bohan A , Peter JB . Polymyositis and dermatomyositis (first of two parts)[J]. N Engl J Med, 1975, 292 (7): 344- 347.
doi: 10.1056/NEJM197502132920706
9 Bohan A , Peter JB . Polymyositis and dermatomyositis (second of two parts)[J]. N Engl J Med, 1975, 292 (8): 403- 407.
doi: 10.1056/NEJM197502202920807
10 Lundberg IE , Tjärnlund A , Bottai M , et al. 2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups[J]. Arthritis Rheumatol, 2017, 69 (12): 2271- 2282.
doi: 10.1002/art.40320
11 Allenbach Y , Mammen AL , Benveniste O , et al. 224th ENMC International Workshop: Clinico-sero-pathological classification of immune-mediated necrotizing myopathies Zandvoort, The Netherlands, 14-16 October 2016[J]. Neuromuscul Disord, 2018, 28 (1): 87- 99.
doi: 10.1016/j.nmd.2017.09.016
12 Oddis CV , Rider LG , Reed AM , et al. International consensus guidelines for trials of therapies in the idiopathic inflammatory myopathies[J]. Arthritis Rheum, 2005, 52 (9): 2607- 2615.
doi: 10.1002/art.21291
13 Aggarwal R , Rider LG , Ruperto N , et al. 2016 American College of Rheumatology/European League Against Rheumatism criteria for minimal, moderate, and major clinical response in adult dermatomyositis and polymyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative[J]. Ann Rheum Dis, 2017, 76 (5): 792- 801.
doi: 10.1136/annrheumdis-2017-211400
14 Tiniakou E , Mecoli CA , Kelly W , et al. Anti-MDA5-positive dermatomyositis and remission in a single referral centre population[J]. Clin Exp Rheumatol, 2023, 41 (2): 309- 315.
15 Rider LG , Werth VP , Huber AM , et al. Measures of adult and juvenile dermatomyositis, polymyositis, and inclusion body myositis: Physician and patient/parent global activity, manual muscle testing (MMT), health assessment questionnaire (HAQ)/childhood health assessment questionnaire (C-HAQ), childhood myositis assessment scale (CMAS), myositis disease activity assessment tool (MDAAT), disease activity score (DAS), short form 36 (SF-36), child health questionnaire (CHQ), physician global damage, myositis damage index (MDI), quantitative muscle testing (QMT), myositis functional index-2 (FI-2), myositis activities profile (MAP), inclusion body myositis functional rating scale (IBMFRS), cutaneous dermatomyositis disease area and severity index (CDASI), cutaneous assessment tool (CAT), dermatomyositis skin severity index (DSSI), skindex, and dermatology life quality index (DLQI)[J]. Arthritis Care Res (Hoboken), 2011, 63 (Suppl 11): S118- S157.
16 Li Y , Li Y , Wu J , et al. Predictors of Poor Outcome of Anti-MDA5-associated rapidly progressive interstitial lung disease in a Chinese cohort with dermatomyositis[J]. J Immunol Res, 2020, 2020, 2024869.
17 Sultan SM , Ioannou Y , Moss K , et al. Outcome in patients with idiopathic inflammatory myositis: Morbidity and mortality[J]. Rheumatology (Oxford), 2002, 41 (1): 22- 26.
doi: 10.1093/rheumatology/41.1.22
18 Lee JS , Lee JE , Hong S , et al. Prognostic factors for steroid-free remission in patients with idiopathic inflammatory myopathies: Importance of anthropometric measurements[J]. Ther Adv Musculoskelet Dis, 2020, 12, 1759720x20936822.
19 Watanabe E , Gono T , Kuwana M , et al. Predictive factors for sustained remission with stratification by myositis-specific autoantibodies in adult polymyositis/dermatomyositis[J]. Rheumatology (Oxford), 2020, 59 (3): 586- 593.
20 Mariampillai K , Granger B , Amelin D , et al. Development of a new classification system for idiopathic inflammatory myopathies based on clinical manifestations and myositis-specific autoanti-bodies[J]. JAMA Neurol, 2018, 75 (12): 1528- 1537.
doi: 10.1001/jamaneurol.2018.2598
21 Watanabe Y , Uruha A , Suzuki S , et al. Clinical features and prognosis in anti-SRP and anti-HMGCR necrotising myopathy[J]. J Neurol Neurosurg Psychiatry, 2016, 87 (10): 1038- 1044.
doi: 10.1136/jnnp-2016-313166
22 Merlonghi G , Antonini G , Garibaldi M . Immune-mediated necrotizing myopathy (IMNM): A myopathological challenge[J]. Autoimmun Rev, 2022, 21 (2): 102993.
doi: 10.1016/j.autrev.2021.102993
23 杨红霞, 田小兰, 江薇, 等. 免疫介导坏死性肌病的临床和病理特征分析[J]. 北京大学学报(医学版), 2019, 51 (6): 989- 995.
24 Tiniakou E , Pinal-Fernandez I , Lloyd TE , et al. More severe disease and slower recovery in younger patients with anti-3-hydro-xy-3-methylglutaryl-coenzyme A reductase-associated autoimmune myopathy[J]. Rheumatology (Oxford), 2017, 56 (5): 787- 794.
25 Day JA , Limaye V . Immune-mediated necrotising myopathy: A critical review of current concepts[J]. Semin Arthritis Rheum, 2019, 49 (3): 420- 429.
doi: 10.1016/j.semarthrit.2019.04.002
26 Redondo-Benito A , Curran A , Villar-Gomez A , et al. Opportunistic infections in patients with idiopathic inflammatory myopathies[J]. Int J Rheum Dis, 2018, 21 (2): 487- 496.
doi: 10.1111/1756-185X.13255
27 Sun S , Chen Z , Zhang D , et al. Description and analysis of a novel subtype of the anti-synthetase syndrome characterized by frequent attacks of fever and systemic inflammation in a single-center cohort study[J]. Front Immunol, 2021, 12, 729602.
doi: 10.3389/fimmu.2021.729602
28 Debray MP , Borie R , Revel MP , et al. Interstitial lung disease in anti-synthetase syndrome: Initial and follow-up CT findings[J]. Eur J Radiol, 2015, 84 (3): 516- 523.
doi: 10.1016/j.ejrad.2014.11.026
29 Hallowell RW , Ascherman DP , Danoff SK . Pulmonary manifestations of polymyositis/dermatomyositis[J]. Semin Respir Crit Care Med, 2014, 35 (2): 239- 248.
doi: 10.1055/s-0034-1371528
30 李玉慧, 姚海红, 张学武, 等. 94例皮肌炎患者器官受累及免疫学特征分析[J]. 北京大学学报(医学版), 2010, 42 (2): 140- 142.
doi: 10.3969/j.issn.1671-167X.2010.02.005
31 Johnson C , Pinal-Fernandez I , Parikh R , et al. Assessment of mortality in autoimmune myositis with and without associated interstitial lung disease[J]. Lung, 2016, 194 (5): 733- 737.
doi: 10.1007/s00408-016-9896-x
32 Chen IJ , Wu YJJ , Lin CW , et al. Interstitial lung disease in polymyositis and dermatomyositis[J]. Clin Rheumatol, 2009, 28 (6): 639- 646.
doi: 10.1007/s10067-009-1110-6
33 Hallowell RW , Danoff SK . Diagnosis and management of myositis-associated lung disease[J]. Chest, 2023, 163 (6): 1476- 1491.
doi: 10.1016/j.chest.2023.01.031
34 Li L , Wang H , Wang Q , et al. Myositis-specific autoantibodies in dermatomyositis/polymyositis with interstitial lung disease[J]. J Neurol Sci, 2019, 397, 123- 128.
doi: 10.1016/j.jns.2018.12.040
35 Srivastava P , Dwivedi S , Misra R . Myositis-specific and myositis-associated autoantibodies in Indian patients with inflammatory myositis[J]. Rheumatol Int, 2016, 36 (7): 935- 943.
doi: 10.1007/s00296-016-3494-3
36 Li Y , Gao X , Li Y , et al. Predictors and mortality of rapidly progressive interstitial lung disease in patients with idiopathic inflammatory myopathy: A series of 474 patients[J]. Front Med (Lausanne), 2020, 7, 363.
37 Jiang W , Shi JL , Yang HX , et al. Long-term outcomes and prognosis factors in patients with idiopathic inflammatory myopathies based on myositis-specific autoantibodies: A single cohort study[J]. Arthritis Care Res (Hoboken), 2023, 75 (5): 1175- 1182.
doi: 10.1002/acr.24993
38 Komac A , Gokcen N , Yazici A , et al. The role of lactate dehydrogenase-to-albumin ratio in clinical evaluation of adult-onset Still's disease[J]. Int J Clin Pract, 2021, 75 (10): e14615.
39 Bohan A , Peter JB , Bowman RL , et al. Computer-assisted analysis of 153 patients with polymyositis and dermatomyositis[J]. Medicine (Baltimore), 1977, 56 (4): 255- 286.
doi: 10.1097/00005792-197707000-00001
40 Tymms KE , Webb J . Dermatopolymyositis and other connective tissue diseases: A review of 105 cases[J]. J Rheumatol, 1985, 12 (6): 1140- 1148.
41 Niu Q , Zhao LQ , Ma WL , et al. A new predictive model for the prognosis of MDA5(+) DM-ILD[J]. Front Med (Lausanne), 2022, 9, 908365.
42 Ding Y , Ge Y . Anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis complicated with macrophage activation syndrome[J]. Ther Adv Chronic Dis, 2022, 13, 20406223221098128.
43 Chen F , Wang D , Shu X , et al. Anti-MDA5 antibody is associa-ted with A/SIP and decreased T cells in peripheral blood and predicts poor prognosis of ILD in Chinese patients with dermatomyositis[J]. Rheumatol Int, 2012, 32 (12): 3909- 3915.
doi: 10.1007/s00296-011-2323-y
44 朱冯赟智, 邢晓燕, 汤晓菲, 等. 肌炎合并血栓栓塞患者的临床及免疫学特征[J]. 北京大学学报(医学版), 2020, 52 (6): 995- 1000.
45 Davalos D , Akassoglou K . Fibrinogen as a key regulator of inflammation in disease[J]. Semin Immunopathol, 2012, 34 (1): 43- 62.
doi: 10.1007/s00281-011-0290-8
[1] Zhicun LI, Tianyu WU, Lei LIANG, Yu FAN, Yisen MENG, Qian ZHANG. Risk factors analysis and nomogram model construction of postoperative pathological upgrade of prostate cancer patients with single core positive biopsy [J]. Journal of Peking University (Health Sciences), 2024, 56(5): 896-901.
[2] Ye YAN,Xiaolong LI,Haizhui XIA,Xuehua ZHU,Yuting ZHANG,Fan ZHANG,Ke LIU,Cheng LIU,Lulin MA. Analysis of risk factors for long-term overactive bladder after radical prostatectomy [J]. Journal of Peking University (Health Sciences), 2024, 56(4): 589-593.
[3] Yan CHEN,Kuangmeng LI,Kai HONG,Shudong ZHANG,Jianxing CHENG,Zhongjie ZHENG,Wenhao TANG,Lianming ZHAO,Haitao ZHANG,Hui JIANG,Haocheng LIN. Retrospective study on the impact of penile corpus cavernosum injection test on penile vascular function [J]. Journal of Peking University (Health Sciences), 2024, 56(4): 680-686.
[4] Bo PANG,Tongjun GUO,Xi CHEN,Huaqi GUO,Jiazhang SHI,Juan CHEN,Xinmei WANG,Yaoyan LI,Anqi SHAN,Hengyi YU,Jing HUANG,Naijun TANG,Yan WANG,Xinbiao GUO,Guoxing LI,Shaowei WU. Personal nitrogen oxides exposure levels and related influencing factors in adults over 35 years old in Tianjin and Shanghai [J]. Journal of Peking University (Health Sciences), 2024, 56(4): 700-707.
[5] Jing HE,Zhongze FANG,Ying YANG,Jing LIU,Wenyao MA,Yong HUO,Wei GAO,Yangfeng WU,Gaoqiang XIE. Relationship between lipid metabolism molecules in plasma and carotid atheroscle-rotic plaques, traditional cardiovascular risk factors, and dietary factors [J]. Journal of Peking University (Health Sciences), 2024, 56(4): 722-728.
[6] Zhengfang LI,Cainan LUO,Lijun WU,Xue WU,Xinyan MENG,Xiaomei CHEN,Yamei SHI,Yan ZHONG. Application value of anti-carbamylated protein antibody in the diagnosis of rheumatoid arthritis [J]. Journal of Peking University (Health Sciences), 2024, 56(4): 729-734.
[7] Shan CAI,Yihang ZHANG,Ziyue CHEN,Yunfe LIU,Jiajia DANG,Di SHI,Jiaxin LI,Tianyu HUANG,Jun MA,Yi SONG. Status and pathways of factors influencing physical activity time among elementary and junior high school students in Beijing [J]. Journal of Peking University (Health Sciences), 2024, 56(3): 403-410.
[8] Zuhong ZHANG,Tianjiao CHEN,Jun MA. Associations between puberty timing and cardiovascular metabolic risk factors among primary and secondary students [J]. Journal of Peking University (Health Sciences), 2024, 56(3): 418-423.
[9] Yuting LIN,Huali WANG,Yu TIAN,Litong GONG,Chun CHANG. Factors influencing cognitive function among the older adults in Beijing [J]. Journal of Peking University (Health Sciences), 2024, 56(3): 456-461.
[10] Jinrong ZHU,Yana ZHAO,Wei HUANG,Weiwei ZHAO,Yue WANG,Song WANG,Chunyan SU. Clinical characteristics of COVID-19 infection in patients undergoing hemodialysis [J]. Journal of Peking University (Health Sciences), 2024, 56(2): 267-272.
[11] Xiaoqian SI,Xiujuan ZHAO,Fengxue ZHU,Tianbing WANG. Risk factors for acute respiratory distress syndrome in patients with traumatic hemorrhagic shock [J]. Journal of Peking University (Health Sciences), 2024, 56(2): 307-312.
[12] Yangyang LI,Lin HOU,Zijun MA,Shanyamei HUANG,Jie LIU,Chaomei ZENG,Jiong QIN. Association of pregnancy factors with cow's milk protein allergy in infants [J]. Journal of Peking University (Health Sciences), 2024, 56(1): 144-149.
[13] Xiaoqiang LIU,Yin ZHOU. Risk factors of perioperative hypertension in dental implant surgeries with bone augmentation [J]. Journal of Peking University (Health Sciences), 2024, 56(1): 93-98.
[14] Wen-gen LI,Xiao-dong GU,Rui-qiang WENG,Su-dong LIU,Chao CHEN. Expression and clinical significance of plasma exosomal miR-34-5p and miR-142-3p in systemic sclerosis [J]. Journal of Peking University (Health Sciences), 2023, 55(6): 1022-1027.
[15] Liang LUO,Yun LI,Hong-yan WANG,Xiao-hong XIANG,Jing ZHAO,Feng SUN,Xiao-ying ZHANG,Ru-lin JIA,Chun LI. Anti-endothelial cell antibodies in predicting early miscarriage [J]. Journal of Peking University (Health Sciences), 2023, 55(6): 1039-1044.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
Copyright © Journal of Peking University (Health Sciences), All Rights Reserved.
Powered by Beijing Magtech Co. Ltd